Influencing CYP Enzymes to Boost Psychiatric Treatment: A Review on Clinical Evidence

F. M. van Hasselt; Y. Coehorst; B. Wilffert; A.J. M. Loonen

doi:10.1055/s-0032-1323752

Pharmacopsychiatry, Inhaltsverzeichnis

Pharmacopsychiatry 2013; 46(02): 43-46
DOI: 10.1055/s-0032-1323752

Review

Influencing CYP Enzymes to Boost Psychiatric Treatment: A Review on Clinical Evidence

F. M. van Hasselt

¹Department of Pharmacy, Section Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands

²Delta Chair on Pharmacotherapy in Psychiatric Patients, University of Groningen, Delta Psychiatric Hospital, Poortugaal, The Netherlands

,

Y. Coehorst

³Lievensberg Ziekenhuis Bergen op Zoom, Bergen op Zoom, The Netherlands

⁴GGZ Westelijk Noord-Brabant, Department of Long-Term Psychiatric Care Horst-Ligne, Bergen op Zoom, The Netherlands

,

B. Wilffert

¹Department of Pharmacy, Section Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands

,

A.J. M. Loonen

¹Department of Pharmacy, Section Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands

²Delta Chair on Pharmacotherapy in Psychiatric Patients, University of Groningen, Delta Psychiatric Hospital, Poortugaal, The Netherlands

⁴GGZ Westelijk Noord-Brabant, Department of Long-Term Psychiatric Care Horst-Ligne, Bergen op Zoom, The Netherlands

› Institutsangaben

Abstract

Introduction:

Therapeutic drug monitoring to optimize blood plasma concentrations is advised for certain psychiatric drugs. The current standard is to change the dose based on the blood plasma concentration. We present an overview that blood plasma concentrations can also be influenced by adding co-medication based on pharmacokinetic knowledge.

Method:

We performed a systematic review in medical databases for pharmaco-enhancing strategies, and we present 2 cases on actively influencing CYP3A4 metabolism.

Results:

4 original studies were selected on strategies to influence CYP metabolism. 2 studies on influencing CYP2D6 metabolism, 2 studies on influencing CYP1A2 metabolism. In all studies an effect of this influence was present.

Discussion:

Ample clinical evidence is present, but shows promising results. Pharmacokinetic knowledge can and should be used in clinical settings to optimize pharmacotherapy for vulnerable patients. Also the access to expensive medication can be increased by reduction of high dosage schemes.

Key words

mental disorders - drug therapy - Cytochrome P-450 CYP3A

Volltext

Referenzen

References
1 Ustun TB. The global burden of mental disorders. Am J Public Health 1999; 89: 1315-1318
2 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
3 Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: Conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem 2004; 11: 297-312
4 Kraus RP, Diaz P, McEachran A. Managing rapid metabolizers of antidepressants. Depress Anxiety 1996-1997; 4: 320-327
5 Lu ML, Lane HY, Chen KP et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000; 61: 594-599
6 Grimm SW, Richtand NM, Winter HR et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61: 58-69
7 P450 drug interaction table [Internet]; 2011 [updated 20-04. Available from: http://medicine.iupui.edu/clinpharm/ddis/table.asp
8 Mihara K, Otani K, Ishida M et al. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Ther Drug Monit 1997; 19: 43-45
9 Albers LJ, Ozdemir V, Marder SR et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: A prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol 2005; 25: 170-174
10 Farmacotherapeutisch kompas [Internet]; 2011 [updated 01-04-2011. Available from: www.fk.cvz.nl
11 Bakken GV, Rudberg I, Molden E et al. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2011; 33 (02) 222-226
12 Hasselstrom J, Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metabol Drug Interact 2006; 21: 187-211
13 Urichuk L, Prior TI, Dursun S et al. Metabolism of atypical antipsychotics: Involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008; 9: 410-418
14 Hanley M, Cancalon P, Widmer W et al. The effect of grapefruit juice on drug disposition. Expert Opinion on Drug Metabolism and Toxicology 2011; 7: 267-286
15 Zhou S. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-322
16 Ingelman-Sundberg M, Sim SC, Gomez A et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526
17 Wille SM, Cooreman SG, Neels HM et al. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 2008; 45: 25-89
18 Laine K, Tybring G, Hartter S et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70: 327-335
19 Hiemke C. Clinical utility of drug measurement and pharmacokinetics: Therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008; 64: 159-166